Neurology · 2007 · 165 citations · 18 references
MedicineNeurologyPsychologyCognitive PsychologyDementiaNeuropsychiatryCapacity AssessmentCognitive AssessmentCognitive ImpairmentDecision-making CapacityNeurocognitive AssessmentNeuropsychological AssessmentCapacity To ConsentCapacity To Consent AssessmentClinical Capacity Assessment ToolsInformed ConsentInformed Consent CapacityMedical Decision-making Capacity AssessmentNeuropsychological BatteriesTreatment Consent Capacity
<b>Objectives: </b> To empirically assess the capacity of patients with amnestic mild cognitive impairment (MCI) to consent to medical treatment under different consent standards (Ss). <b>Methods: </b> Participants were 56 healthy controls, 60 patients with MCI, and 31 patients with mild Alzheimer disease (AD). Each participant was administered the Capacity to Consent to Treatment Instrument (CCTI) and a comprehensive neuropsychological battery. Group differences in performance on the CCTI and neuropsychological variables were examined. In addition, the capacity status (capable, marginally capable, or incapable) of each MCI participant on each CCTI standard was examined using cut scores derived from control performance. <b>Results: </b> Patients with MCI performed comparably to controls on minimal consent standards requiring merely expressing a treatment choice (S1) or making the reasonable treatment choice [S2], but significantly below controls on the three clinically relevant standards of appreciation (S3), reasoning (S4), and understanding (S5). In turn, the MCI group performed significantly better than the mild AD group on [S2], S4, and S5. Regarding capacity status, patients with MCI showed a progressive pattern of capacity compromise (marginally capable and incapable outcomes) related to stringency of consent standard. <b>Conclusions: </b> Patients with amnestic mild cognitive impairment (MCI) demonstrate significant impairments on clinically relevant abilities associated with capacity to consent to treatment. In obtaining informed consent, clinicians and researchers working with patients with MCI must consider the likelihood that many of these patients may have impairments in consent capacity related to their amnestic disorder and related cognitive impairments. <b>GLOSSARY: </b><b>AD</b> = Alzheimer disease; <b>ADRC</b> = Alzheimer9s Disease Research Center; <b>CCTI</b> = Capacity to Consent to Treatment Instrument; <b>CVLT-II</b> = California Verbal Learning Test, second edition; <b>DRS-2</b> = Dementia Rating Scale, 2nd edition; <b>GDS</b> = Geriatric Depression Scale; <b>MCI</b> = mild cognitive impairment; <b>MDC</b> = medical decision-making capacity; <b>MMSE</b> = Mini-Mental State Examination; <b>Ss</b> = consent standards; <b>WAIS-III</b> = Wechsler Adult Intelligence Scale, third edition; <b>WMS-III</b> = Wechsler Memory Scale, third edition; <b>WMS-R</b> = Wechsler Memory Scale, revised edition; <b>WRAT-3</b> = Wide Range Achievement Test, third edition.
18
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald Petersen, Ronald G. Thomas, Michael Grundman et al. · New England Journal of Medicine · 2005 · 1.9K citations · Full text
Appendix G: Geriatric Depression Scale
William J. Marks · 2015 · 1.5K citations